Health AI Central
Share:
Peer-Reviewed Publication
Diagnostics (Basel)2026;16(7)March 29, 2026Journal Article

Analytical Validation of Multimodal AI Test Predicting Breast Cancer Recurrence Risk (Ataraxis Breast RISK).

Marc Dantone1, Martin Lacsamana1, Ken G Zeng1, Paraic A Kenny2, Krzysztof J Geras1, Jan Witowski1
1Ataraxis AI, New York, NY 10016, USA.
2Gundersen Health System, La Crosse, WI 54601, USA.
PubMed PMC DOI PDF

Abstract

Background/Objectives: Breast cancer recurrence risk stratification has relied on gene expression tests that are limited by long turnaround times and consumption of valuable tissue. Artificial intelligence (AI) utilizing digital pathology images elucidates novel morphological biomarkers with strong prognostic associations, but the use of such AI models requires a modified analytical validation app…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.